147388-83-8

ABT-418 (CAS 147388-83-8) is an agonist at neuronal nicotinic acetylcholine receptors displaying the highest potency at α4β2 and α2β2 subtypes (EC50= approximately 6 and 11 μM, respectively).1 Displays anxiolytic activity in a rat model and was 6-fold more potent than diazepam.2 Reduces distractibility in a primate model3 and may have relevance in attention deficit hyperactivity disorder4. Improves cognition in Alzheimer’s disease patients.5

ABT-418 Hydrochloride is a neuronal nicotinic acetylcholine receptor agonist or activator which can be synthesized from L-proline.

4°C, away from moisture

1) Papke et al. (1997), Activation and inhibition of rat neuronal nicotinic receptors by ABT-418; Br. J. Pharmacol., 120 429 2) Brioni et al. (1994), Anxiolytic-like effects of the novel cholinergic channel activator ABT-418; J. Pharmacol. Exp. Therap., 271 353 3) Prendergast et al. (1998), Central nicotinic receptor agonists ABT-418, ABT089, and (-)-nicotine reduce distractibility in adult monkey; Psychopharmacology (Berl), 136 50 4) Beiderman and Spencer (2000), Non-stimulant treatments for ADHD; Eur. Child Adolesc. Psychiatry, 9 Suppl1 151 5) Potter et al. (1999), Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer’s disease; Psychopharmacology (Berl), 142 334